Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
Trend | Peers | Company |
---|---|---|
Is return on equity increasing? | Yes | No |
Is net profit margin increasing? | Yes | No |
Is asset turnover increasing? | Yes | Yes |
Is equity multiplier increasing? | Yes | Yes |
Competitors Used |
---|
Amphastar Pharmaceuticals, Inc. |
Xeris Biopharma Holdings, Inc. |
Endo, Inc. |
Organon & Co. |
Viatris Inc. |
Return on Equity Benchmarks | ||||||||
Comparable Companies | ||||||||
AMPH | XERS | NDOI | OGN | VTRS | HTD | |||
Return On Equity | ||||||||
Latest Twelve Months | 20% | 203% | -195% | 254% | -21% | 22% | ||
Fiscal Year - 1 | 24% | -324% | 45% | -213% | 0% | 21% | ||
Fiscal Year - 2 | 19% | -135% | 108% | -76% | 10% | 23% | ||
Fiscal Year - 3 | 15% | -190% | 60% | 68% | -6% | 25% | ||
Fiscal Year - 4 | 0% | -378% | -33% | 36% | -4% | 24% | ||
Fiscal Year - 5 | 14% | -280% | 53% | 49% | 0% | 29% | ||
Average | 15% | -184% | 6% | 20% | -3% | 24% | ||
Median | 17% | -235% | 49% | 43% | -2% | 23% | ||
Benchmarks | Ticker | |||||||
Amphastar Pharmaceuticals, Inc. | NasdaqGS:AMPH | |||||||
Xeris Biopharma Holdings, Inc. | NasdaqGS:XERS | |||||||
Endo, Inc. | OTCPK:NDOI | |||||||
Organon & Co. | NYSE:OGN | |||||||
Viatris Inc. | NasdaqGS:VTRS |
Financial Performance | ||||||||
Comparable Companies | ||||||||
(in millions) | AMPH | XERS | NDOI | OGN | VTRS | HTD | ||
Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
LTM Period | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | ||
Revenues | ||||||||
Latest Twelve Months | 731 | 223 | 1,733 | 6,294 | 14,330 | 685 | ||
Fiscal Year | 732 | 203 | 1,760 | 6,403 | 14,739 | 675 | ||
Fiscal Year - 1 | 644 | 164 | 2,012 | 6,263 | 15,427 | 482 | ||
Fiscal Year - 2 | 499 | 110 | 2,319 | 6,174 | 16,263 | 402 | ||
Fiscal Year - 3 | 438 | 50 | 2,993 | 6,304 | 17,886 | 366 | ||
Fiscal Year - 4 | 350 | 20 | 2,903 | 6,532 | 11,946 | 354 | ||
Fiscal Year - 5 | 322 | 3 | 2,914 | 7,777 | 11,501 | 306 | ||
Net Income | ||||||||
Latest Twelve Months | 142 | (45) | 5,485 | 750 | (3,790) | 133 | ||
Fiscal Year | 160 | (55) | 5,460 | 864 | (634) | 140 | ||
Fiscal Year - 1 | 138 | (62) | (2,448) | 1,023 | 55 | 105 | ||
Fiscal Year - 2 | 91 | (95) | (2,910) | 917 | 2,079 | 101 | ||
Fiscal Year - 3 | 62 | (123) | (569) | 1,351 | (1,269) | 113 | ||
Fiscal Year - 4 | 1 | (91) | 247 | 2,256 | (670) | 106 | ||
Fiscal Year - 5 | 49 | (126) | (361) | 3,306 | 17 | 94 | ||
Total Assets | ||||||||
Latest Fiscal Quarter Prior | 1,574 | 337 | 4,950 | 11,891 | 47,344 | 656 | ||
Latest Fiscal Quarter | 1,626 | 315 | 4,191 | 13,156 | 38,475 | 846 | ||
Fiscal Year | 1,577 | 323 | 4,353 | 13,101 | 41,501 | 841 | ||
Fiscal Year - 1 | 1,513 | 323 | 5,137 | 12,058 | 47,686 | 622 | ||
Fiscal Year - 2 | 742 | 345 | 5,758 | 10,955 | 50,022 | 583 | ||
Fiscal Year - 3 | 672 | 304 | 8,767 | 10,681 | 54,843 | 424 | ||
Fiscal Year - 4 | 631 | 159 | 9,265 | 10,109 | 61,553 | 572 | ||
Fiscal Year - 5 | 587 | 109 | 9,390 | 10,548 | 31,256 | 412 | ||
Fiscal Year - 6 | 514 | 120 | 10,132 | 10,494 | 32,735 | 312 | ||
Common Equity | ||||||||
Latest Fiscal Quarter Prior | 672 | (9) | (6,755) | 48 | 20,014 | 548 | ||
Latest Fiscal Quarter | 751 | (35) | 1,126 | 542 | 15,650 | 683 | ||
Fiscal Year | 732 | (30) | 1,252 | 472 | 18,636 | 680 | ||
Fiscal Year - 1 | 639 | (7) | (6,598) | (70) | 20,467 | 507 | ||
Fiscal Year - 2 | 529 | 45 | (4,162) | (892) | 21,072 | 502 | ||
Fiscal Year - 3 | 446 | 95 | (1,244) | (1,508) | 20,493 | 376 | ||
Fiscal Year - 4 | 402 | 34 | (648) | 5,486 | 22,954 | 523 | ||
Fiscal Year - 5 | 381 | 14 | (867) | 7,035 | 11,884 | 371 | ||
Fiscal Year - 6 | 332 | 75 | (498) | 6,348 | 12,167 | 276 |